Company

Management

Jeffrey D. Bloss, M.D.
Chief Medical Officer

Dr. Bloss is responsible for leading the clinical development of Xencor's product pipeline and for overseeing regulatory affairs at the company. Most recently, he was the Vice President of Clinical Development at Onyx Pharmaceuticals, Inc. where he led the development for sorafenib. Prior to that, he led the development teams for Tarceva® (erlotinib) and pertuzimab as a group medical director at Genentech, and he worked on Gemzar® (gemcitabine HCI), Alimta® (pemetrexed) and the other pipeline drugs as the U.S. Director of Oncology at Eli Lilly and Company. Before joining Eli Lilly, Dr. Bloss served at the University of Missouri-Columbia as both the Director of the Office of Clinical Research and Compliance and as the Director of the Division of Gynecologic Oncology. Dr. Bloss also held senior medical positions with the United States Air Force Medical Corps. He received an M.D. from Thomas Jefferson University and a B.S. from Juniata College.